In support of GPNMB as a therapeutic target in cancer, a previous study of ASPSCR1-TFE3 fusion-driven alveolar soft part sarcoma also demonstrated increased GPNMB expression, and Gpnmb silencing in a mouse model of this disease inhibited cell migration, suggesting a role in metastasis [51]. Here, ASPSCR1 is linked to alveolar soft part sarcoma.